Colorectal cancer (CRC) is the second leading cause of cancer death for cancers that affect both men and women in the United States, following lung cancer.
The linkage also unveiled significant regional variation in AI/AN colorectal cancer incidence.
Screening can lower CRC incidence and mortality. 6 Removing premalignant polyps can prevent the disease, and diagnosing CRC at an earlier stage offers significant survival benefit. 7, 8 AI/AN screening lags significantly behind that of Whites. 9 Although this would portend higher CRC death rates among AI/AN persons than in Whites, more accurate data on CRC mortality differences are needed. We applied a linkage methodology to both incidence and mortality data to more accurately characterize CRC incidence and mortality for AI/AN persons by region.
METHODS
Detailed methods for generating the analytical mortality files are described elsewhere in this supplement. 10 Detailed methods describing incidence data and analysis are available in a previous publication. 4 An abbreviated description of our methods follows.
Data Sources
Population estimates. Bridged single-race population estimates developed by the US Census Bureau and the Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS), which were adjusted for population shifts because of Hurricanes Katrina and Rita in 2005, are included as denominators in the calculations of death rates. 11, 12 Bridged single-race data allow for comparability between the pre-and post-2000 race/ethnicity population estimates. During preliminary analyses, we discovered that the updated bridged intercensal populations estimates significantly overestimated AI/AN persons of Hispanic origin. 13 Therefore, to avoid underestimating incidence and mortality in AI/AN populations, our analyses were limited to non-Hispanic AI/AN individuals. We chose Non-Hispanic Whites as the most homogeneous referent group. Henceforth, the qualifying term "non-Hispanic" is omitted when discussing both groups. Death records. Death certificate data are compiled by each state and sent to the NCHS, where they are edited for consistency and stripped of personal identifiers. NCHS publishes this information as part of the National Vital Statistics System (NVSS) and includes underlying and multiple cause of death fields, state of residence, age, gender, race, and ethnicity.
14 NCHS applies a bridging algorithm nearly identical to that used by the Census Bureau to assign a single race to decedents with multiple races on their death certificates.
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The IHS patient registration database was linked to death certificate data in the National Death Index to identify AI/AN deaths misclassified as non-Native. 10 Following Race for AI/AN deaths in this report were based on criteria described elsewhere in this supplement, combining race classification by NCHS based on the death certificate and information from data linkages between the IHS patient registration database and the National Death Index. 10 For deaths between 1990 and 1998, the underlying cause of death was coded according to the International Classification of Diseases, Ninth Revision (ICD-9).
15b
For 1999 to 2009, the ICD-10 was used.
15c
Incidence data. We identified incidence of CRC cases between 1999 and 2009 from population-based central cancer registries in the CDC National Program of Cancer Registries (NPCR) 16 and the NCI Surveillance, Epidemiology, and End Results (SEER) program. 17 For data to be included for a given year, registries had to meet data standards developed for the US Cancer Statistics report. 16 Participating registries classified tumor histology, tumor behavior, and primary cancer site according to the International Classification of Diseases for Oncology, Third Edition (ICD-O-3). 18 To identify CRC cases among AI/ANs misclassified as other races, we linked central cancer registries to cancer registry records with IHS patient registration files as previously described. 4, 16, 19 Stage at diagnosis was based on the SEER summary staging system: localized (confined to colon or rectum); regional (direct extension of the cancer to adjacent organs or tissues, or to regional lymph nodes); distant (metastasis to other areas of the body); and unstaged. 20 Stage was then grouped into early (localized) and late (regional or distant) categories. Geographic coverage. Final analyses were restricted to Contract Health Service Delivery Area (CHSDA) counties that contained federally recognized tribal lands or are adjacent to tribal lands (Figure 1) . 10 CHSDA residence is used by the IHS to determine eligibility for services not directly available within the IHS. Linkage studies indicate less racial misclassification for AI/AN persons in these counties. 10, 21 CHSDA counties also have higher proportions of AI/AN persons than do non-CHSDA counties, with 64% of AI/AN individuals residing in the 637 CHSDA counties (representing 20% of the 3141 counties in the United States). Although less geographically representative, we used analyses restricted to CHSDA counties for incidence and death rates to improve accuracy in interpreting AI/AN colorectal cancer statistics.
We completed analyses for all regions combined and by individual IHS regions: Northern Plains, Alaska, Southern Plains, Southwest, Pacific Coast, and East ( Figure 1) . 10 We used identical or similar regional analyses for other health-related publications focusing on AI/AN persons. 22---24 We found regional strata to be preferable to using smaller jurisdictions, such as the administrative areas defined by IHS, 25 which yielded less stable estimates. Additional details about CHSDA counties and IHS regions are provided elsewhere (Table 1) . 10 
Statistical Methods
All rates, expressed per 100 000 population, were directly age-adjusted, using SEER*Stat software, to the 2000 US standard population and should not be compared with published incidence and death rates adjusted using a different standard.
Using age-adjusted incidence and death rates, we calculated standardized rate ratios (RRs) for AI/AN persons compared with Whites. We calculated RRs by SEER*Stat to the fourth decimal place and rounded the RRs for presentation. We calculated confidence intervals (CIs) for age-adjusted rates and RRs using SEER*Stat 8.0.2 based on the methods described by Tiwari et al. 26 Temporal changes in annual age-adjusted incidence and death rates, including the annual percent change (APC) for each interval, were assessed with joinpoint regression techniques using statistical software developed by the NCI. 27 Statistical significance was set at a P value of less than .05. We evaluated CRC mortality trends for 1990 to 2009 and reported them as the APC of the age-adjusted rates. If a joinpoint (change in trend) was identified during this period, the average annual percent change (AAPC) for the 10-year period 2000 to 2009 was reported. If no joinpoint was identified, the 20-year APC and the 10-year AAPC would be the same. Subtracting the mortality/incidence ratio from 1 approximated the probability of 5-year survival, and was shown to be reliable for use with CRC rates. 28 The all-counties CRC incidence rate was 10% lower (P < .05) among AI/AN individuals compared with Whites; the death rate was 11% higher (P < .05). For CHSDA counties only, the CRC incidence rate was 21% higher (P < .05) among AI/AN individuals, and the death rate 39% higher, with similar elevations for both men and women. The remainder of the results referred to CHSDA counties only. AI/AN colorectal cancer incidence varied regionally ( Table 1 ). The rate among AI/AN populations was significantly higher (P < .05) than for Whites in 4 regions (Northern Plains, Alaska, Southern Plains, and Pacific Coast), and significantly lower (P < .05) in 2 regions (East and Southwest). This pattern was seen among both men and women, although it was not always statistically significant. Regional CRC incidence rates for both genders combined varied by 199% among AI/AN populations (31.0 in the Southwest to 92.7 in Alaska), but only by 17% among Whites.
RESULTS

From
CRC death rates also showed significant regional differences. The risk of dying from CRC was elevated (P < .05) among AI/AN persons in the same 4 regions with elevated incidence (Northern Plains, Alaska, Southern Plains, and Pacific Coast; Table 1 ). In the other 2 regions AI/AN death RRs were either not statistically significant (East) or lower by a similar magnitude as for incidence (Southwest). Regional CRC death rates for both genders combined varied by 173% among AI/AN persons (12.1 in the Southwest to 33.0 in Alaska) and by only 23% among White CHSDA residents.
The mortality/incidence RR for CHSDA residents as a whole was 0.42 (95% = CI 0.39, 0.58) for AI/AN individuals compared with 0.36 (95% CI = 0.36, 0.37) for Whites; this difference was similar for men and women. The mortality/incidence RR was higher for AI/AN individuals than Whites in each region, except the Southwest. The East, which had a significantly lower CRC incidence rate for AI/AN persons, had the highest mortality/incidence RR among AI/AN persons, and showed the most within region difference from Whites.
Age at Diagnosis
When data from all regions were combined, AI/AN individuals had an increased risk of CRC diagnosis compared with Whites in all age strata. This risk was 45% higher for men and women younger than 50 years, 32% higher among those aged 50 to 64 years, and 13% higher among those aged 65 years or older (all P < 0.05) ( Table 2) .
By region, AI/AN persons in the Northern Plains, Alaska, and the Southern Plains had increased incidence of CRC among all age groups. In the Pacific Coast, there was a significant increased risk among AI/AN persons aged 65 years and older, and nonsignificant increases in other age groups. In the East, there was significantly lower incidence among AI/AN persons aged 65 years and older compared with Whites and a nonsignificant decreased risk in the other age groups, the largest difference being for persons younger than 50 years. In the Southwest, there was a 37% lower incidence of CRC among AI/AN persons aged 65 years and older, whereas AI/AN persons younger than 50 years had a 34% higher incidence compared with Whites.
Stage at Diagnosis
The age-adjusted rate of early stage CRC was 9% higher among AI/AN individuals compared with Whites for both genders combined, whereas the rate of late-stage CRC was 25% higher (Table 3 ). In the Northern Plains, Alaska, and Southern Plains, the rate of both early-and late-stage CRC were consistently elevated among AI/AN individuals, although the increase in risk was larger for late-stage disease. This was reflected in higher late-to early stage RRs among AI/AN individuals compared with Whites in these regions.
Colorectal Cancer Incidence Trends
CRC incidence trends were evaluated for 1999 to 2009 and reported as the APC in the age-adjusted rate ( Table 4 ). The age-adjusted CRC incidence rate among Whites in CHSDA counties significantly decreased (P <
When all CHSDA counties were combined, there was no significant change in CRC incidence rate among AI/AN populations between 1999 and 2009. Only Alaska (3.1% per year) and the Pacific Coast (1.9% per year) had a significant decrease in AI/AN colorectal cancer incidence rate during this period. In the Southwest, CRC incidence rates among AI/AN populations significantly increased at 7. 
Mortality Trends
The age-adjusted CRC death rate among Whites significantly (P < .05) decreased in every region from 1990 to 2009 (Table 4) . In most regions, the decrease in death rates accelerated in the latest decade, with a combined decline of 3.1% per year between 2000 and 2009.
Conversely, CRC death rates among AI/AN persons showed no statistically significant change when regional data were combined. 
DISCUSSION
The purpose of our study was to characterize estimates of CRC incidence and mortality in Continued AI/AN persons by region compared with Whites using a linkage methodology to improve AI/AN classification in the incidence and mortality data. Restricting the study population to CHSDA counties unveiled significantly higher incidence and death rates among AI/AN persons compared with those for all US counties. The difference between the CHSDA and all counties rates was likely driven by higher rates of misclassification in the cancer registries and death records for AI/AN persons living in urban and other non-CHSDA areas. 3 Our previous application of this method examined incidence from 1999 to 2004. 5 In that analysis, the overall CHSDA CRC incidence was 9% lower among all AI/AN populations than Whites; however, the AI/AN rate varied approximately 5-fold regionally, from 21.0 in the Southwest to 102.6 in Alaska. Over the subsequent 5 years covered in this report, CRC incidence among AI/AN persons increased from 46.3 to 52.5, whereas it decreased among Whites from 50.8 to 43.4. Hence, although rates decreased steadily in Whites across regions, the incidence in AI/AN individuals fell in only Alaska and the Pacific Coast, albeit at a slower rate. Meanwhile, incidence did not significantly change in the other regions from 2005 to 2009. Others reported a steady decline in the US CRC incidence rate, driven primarily by downward trends among Whites. 29 The accelerated decline in recent years was primarily attributed to the efficacy of removing precancerous polyps during screening colonoscopy. 30 Significant disparities existed between Whites and AI/ANs in the use of CRC screening, especially with endoscopic screening. 31 Reasons for these disparities were multifactorial, but included a lack of endoscopic services at most IHS and tribal facilities, underfunded referral systems, and fecal occult blood testing (with either guaiac or fecal immunochemical methods) as the primary CRC screening modality employed by the majority of IHS and tribal facilities. Although effective at finding CRC before symptoms arise, fecal testing does not remove precancerous polyps, which can be removed during endoscopic screening. 6 Data from the 2010 National Health Interview Survey reported 59.8% of Whites to be current with screening guidelines compared with 49.5% of AI/AN persons. 9 The Government
Performance Results Act requires IHS-funded facilities to submit CRC screening data. In 2010, 37% of AI/AN men and women served by the IHS were current with screening guidelines, although rates ranged from 24% in the IHS Phoenix area to 55% in the IHS Alaska area. 32 Because screening rates significantly rose over the last decade, as has the use of endoscopic screening, more time might be needed to see an effect on incidence and mortality. 32 Between 2005 and 2009, AI/AN persons in Alaska had a 115% greater CRC incidence rate and a 132% greater death rate than Whites. The Alaska Area program has been responding to this disparity with innovative programs designed to increase screening, including the deployment of itinerant colonoscopy teams who travel to regional health centers. 33 The
Northern Plains had the second highest CRC incidence and death rate, but was distinguished by being the only region with a significantly declining death rate. Innovative communitybased programs such as Minnesota's Intertribal Colorectal Cancer Council, which brings together tribal health champions to improve screening, and the Wisdom Steps program, which rewards elders for meeting preventative health measures, might be affecting this change. 34, 35 By comparison, between 2005 and 2009, the incidence of CRC among Southwest AI/AN persons was more than 21% lower than Whites. Despite lower CRC burden, the incidence of CRC among Southwest AI/AN persons increased at an alarming rate of 7.7% per year between 1999 and 2005, whereas mortality increased at 1.3% per year. Work is needed to identify the factors behind these concerning trends. The reasons for the substantial interregional variation in AI/AN colorectal cancer incidence and mortality were unclear, but were likely multifactorial. Genetic differentiation might play a role in these diverse, often isolated communities. 36 AI/AN populations also vary widely in their diets, environments, and access to care. Many Alaskan AI/AN persons maintain subsistence diets high in animal fats and low in fresh fruits and vegetables. 37 The high cigarette smoking rate and high prevalence of vitamin D deficiency because of low dietary intake and low ultraviolet B exposure could also play a role. 38, 39 By comparison, AI/AN persons in the Southwest have lower cigarette smoking use, 40 whereas year-round ultraviolet B exposure results in lower rates of vitamin D deficiency. 38 Given the dramatic regional CRC differences among AI/AN populations, these populations might be ideally suited for further research into the influence of risk factors, such as diet, environment, genetics, and screening on CRC mortality. Such findings might have important implications for all populations. Understanding the relationship between CRC incidence and age at diagnosis is critical for informing screening guidelines. The rationale for when to begin screening is based on the benefit of early stage diagnoses in terms of added life-years, attenuated by the risk of screening. 6 In this study, the incidence rate of CRC cases occurring in AI/AN individuals younger than age 50 years ranged from 5.4 in the East to 15.4 in Alaska. By comparison, the rate among Whites ranged from 5.7 in the Southwest to 7.3 in the Southern Plains. Although the American College of Gastroenterology recommends CRC screening beginning at age 50 years in average-risk persons, it recommends that African Americans begin screening at age 45 years because they were shown to acquire a survival benefit from screening at a younger age. 41 Given our data, modeling the risks and benefits of earlier age CRC screening in AI/AN individuals might be warranted. Based on the mortality/incidence ratio, AI/ANs diagnosed with CRC had a lower 5-year survival probability than Whites in all IHS regions, with exception of the Southwest, where it was the same. A major predictor of CRC mortality odds was stage at diagnosis. Five-year survival was more than 90% for CRC Additional factors likely played a role in survival disparities. Proximity to a cancer center, the availability of resources to pay for care, patient comorbidities, and patient acceptance of treatment could all affect cancer outcomes. 43, 44 A better understanding of how these factors affected AI/AN colorectal cancer survival disparities is needed. Our results must be considered in light of several limitations. Although we approximated survival probability, making inferences about the relationship between incidence and mortality based on 5 years of data was problematic. Incident cases might die from CRC after the catchment period, whereas mortality cases might have been diagnosed before catchment. Linking incidence and mortality so case---fatality ratios might be discerned would better characterize survival disparities.
It was also probable that our reported incidence and death rates for CRC in AI/AN populations were still underestimates. The IHS provides care to 2.2 million of the estimated 3.4 million AI/AN persons in the United States. 45 Individuals who self-identified as AI/AN persons on census records, but did not have direct tribal ties, were from non-federally recognized tribes, lived long distances from IHS and tribal health facilities, were multiracial, were less likely to access the IHS. 46 AI/AN residents of urban areas might also differ from all AI/AN persons in poverty level, health care access, and other factors that might influence mortality. 47, 48 Our approach could not correct racial misclassification in these cases. Furthermore, there was substantial variation between federally recognized tribes in the proportion of Native ancestry required for tribal membership, and therefore, for eligibility for IHS services. Whether and how this discrepancy in tribal membership requirements might influence some of our findings was unclear, although our findings were consistent with previous reports. Finally, although the exclusion of Hispanic AI/AN persons from the analyses reduced the overall count of deaths in AI/AN persons by less than 5%, it might disproportionately exclude some tribal members in some states. This study found dramatic geographic variations in AI/AN colorectal cancer incidence and mortality compared with Whites. Future presentations of AI/AN cancer data should consider the effects of racial misclassification and regional variations might have on summary statistics. The higher prevalence of advanced disease at diagnosis and corresponding mortality disparities among AI/AN populations call for more attention to improve access to and utilization of CRC screening programs. An understanding of the factors driving these regional disparities could offer critical insights for prevention and control programs. j 
About the Authors
Human Participant Protection
Human participant protection was not required because no human participants were involved. 
